The liver's ability to process fats has become a defining health challenge of our metabolic age, with implications extending far beyond digestive wellness into cardiovascular mortality and cancer risk. What was once considered a relatively uncommon condition now represents the most prevalent chronic liver disease globally, fundamentally reshaping how clinicians approach metabolic health screening.
Metabolic dysfunction-associated steatotic liver disease (MASLD) currently affects 30-40% of adults worldwide, with dramatically higher rates among those with existing metabolic disorders—reaching 60-70% in type 2 diabetics and 70-80% in individuals with obesity. The condition encompasses a spectrum from simple fat accumulation without inflammation to metabolic dysfunction-associated steatohepatitis (MASH), where inflammatory processes compound the fatty infiltration. Diagnosis relies on ultrasonographic evidence of hepatic steatosis combined with at least one metabolic syndrome feature, while excluding other causes like medication effects or viral hepatitis.
This prevalence surge reflects the intersection of sedentary lifestyles, processed food consumption, and rising obesity rates across developed and developing nations. Unlike previous liver disease paradigms focused on alcohol or viral causes, MASLD represents a metabolic epidemic with cascading systemic effects. The condition's association with increased mortality from liver complications, hepatocellular carcinoma, cardiovascular disease, and certain cancers positions it as a sentinel marker for broader metabolic dysfunction. For longevity-focused adults, MASLD prevalence data suggests that liver health monitoring should become routine metabolic surveillance, particularly given the condition's often asymptomatic early stages and its role as both consequence and contributor to metabolic syndrome.